- Oral Abstract Session - Immunotherapy
- Poster Discussion Session - Immunotherapy
- Oral Abstract Session - Molecularly Targeted Agents and Tumor Biology Primary
- Poster Discussion Session - Molecularly Targeted Agents and Tumor Biology Primary
Oral Abstract Session - Immunotherapy
Abstract 2500: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
Presenter: Ulka N. Vaishampayan, MD | University of Michigan Cancer Center
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2500
----------------------------------------------------------------------------------------------------------------------------
Abstract 2501: First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
Presenter: Aung Naing
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2501
----------------------------------------------------------------------------------------------------------------------------
Abstract 2502: Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Presenter: Elena Garralda
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2502
----------------------------------------------------------------------------------------------------------------------------
Abstract: 2503: Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors.
Presenter: Melissa Lynne Johnson
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2503
----------------------------------------------------------------------------------------------------------------------------
Abstract 2504: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).
Presenter: Gerald Steven Falchook
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2504
----------------------------------------------------------------------------------------------------------------------------
Abstract 2505: Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.
Presenter: Martin Gutierrez
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2505
----------------------------------------------------------------------------------------------------------------------------
Abstract 2506: A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Presenter: Sanjay Goel
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2506
----------------------------------------------------------------------------------------------------------------------------
Abstract 2507: Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.
Presenter: Steven Michael Blum
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2507
----------------------------------------------------------------------------------------------------------------------------
Abstract 2508: Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.
Presenter: Abdul Rafeh Naqash
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2508
----------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration
----------------------------------------------------------------------------------------------------------------------------
POSTER SESSION
Immunotherapy
https://meetings.asco.org/2022-asco-annual-meeting/14355?presentation=210135#210135
Poster Discussion Session - Immunotherapy
Abstract 2512: Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.
Presenter: Ye Guo | Poster: 168
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2512
------------------------------------------------------------------------------------------------------------------------
Abstract 2513: A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Presenter: Philippe L. Bedard, | Poster: 169
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2513
------------------------------------------------------------------------------------------------------------------------
Abstract 2514: Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.
Presenter: Aung Naing | Poster: 170
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2514
------------------------------------------------------------------------------------------------------------------------
Abstract 2515: First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).
Presenter: Marwan Fakih | Poster: 171
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2515
------------------------------------------------------------------------------------------------------------------------
Abstract 2516: Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.
Presenter: Vinod P. Balachandran | Poster: 172
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2516
------------------------------------------------------------------------------------------------------------------------
Abstract 2517: Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.
Presenter: Siqing Fu | Poster: 173
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2517
------------------------------------------------------------------------------------------------------------------------
Abstract: 2518: Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.
Presenter: Julius Strauss | Poster: 174
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2518
------------------------------------------------------------------------------------------------------------------------
Abstract 2519: Identifying mechanisms of acquired immune escape from sequential, paired biopsies.
Presenter: F. Stephen Hodi | Poster: 175
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2519
------------------------------------------------------------------------------------------------------------------------
Abstract 2520: Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
Presenter: Jacob Stephen Thomas | Poster: 176
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2520
------------------------------------------------------------------------------------------------------------------------
Abstract 2521: First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
Presenter: Eugene R Ahn | Poster: 177
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2521
------------------------------------------------------------------------------------------------------------------------
Abstract 2522: The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.
Presenter: Anna Claire Olsson-Brown | Poster: 178
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2522
------------------------------------------------------------------------------------------------------------------------
Abstract 2523: Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.
Presenter: Arthur Daban | Poster: 179
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2523
------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration
Oral Abstract Session - Molecularly Targeted Agents and Tumor Biology Primary
Abstract 3000: A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.
Presenter: Lingying Wu
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3500
----------------------------------------------------------------------------------------------------------------------------
Abstract 3001: Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Rahul Raj Aggarwal
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3501
----------------------------------------------------------------------------------------------------------------------------
Abstract 3002: Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).
Presenter: Erika P. Hamilton
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3502
----------------------------------------------------------------------------------------------------------------------------
Abstract 3003: First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Presenter: Ecaterina Elena Dumbrava
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3503
----------------------------------------------------------------------------------------------------------------------------
Abstract 3004: A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS).
Presenter: Mrinal M. Gounder
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3504
----------------------------------------------------------------------------------------------------------------------------
Abstract 3005: A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.
Presenter: Mark Yarchoan
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3505
----------------------------------------------------------------------------------------------------------------------------
Abstract 3006: CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.
Presenter: Daniel R. Carrizosa,
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3506
----------------------------------------------------------------------------------------------------------------------------
Abstract 3007: Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.
Presenter: Yohann Loriot
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3507
----------------------------------------------------------------------------------------------------------------------------
Abstract 3008: Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.
Presenter: Funda Meric-Bernstam
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3508
----------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration
----------------------------------------------------------------------------------------------------------------------------
POSTER SESSION
Molecularly Targeted Agents and Tumor Biology Primary
https://meetings.asco.org/2022-asco-annual-meeting/14358?presentation=210903#210903
Poster Discussion Session - Molecularly Targeted Agents and Tumor Biology Primary
Abstract 3009: Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Presenter: Kieuhoa Tran Vo | Poster: 1
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3009
------------------------------------------------------------------------------------------------------------------------
Abstract 3010: Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Presenter: Anne S. Tsao | Poster: 2
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3010
------------------------------------------------------------------------------------------------------------------------
Abstract 3011: A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
Presenter: Xiaojie Hu | Poster: 3
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3011
------------------------------------------------------------------------------------------------------------------------
Abstract 3012: NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
Presenter: Liza C Villaruz | Poster: 4
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3012
------------------------------------------------------------------------------------------------------------------------
Abstract 3013: First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
Presenter: Sarina Anne Piha-Paul | Poster: 5
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3013
------------------------------------------------------------------------------------------------------------------------
Abstract 3014: Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.
Presenter: T.R. Jeffry Evans | Poster: 6
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3014
------------------------------------------------------------------------------------------------------------------------
Abstract 3015: Expanding clinical actionability in individual patient profiles with the Molecular Oncology Almanac.
Presenter: Brendan Michael Reardon | Poster: 7
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3015
------------------------------------------------------------------------------------------------------------------------
Abstract 3016: Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).
Presenter: Arnaud Bayle | Poster: 8
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3016
------------------------------------------------------------------------------------------------------------------------
Abstract 3017: Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.
Presenter: Matthew Mackay | Poster: 9
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3017
------------------------------------------------------------------------------------------------------------------------
Abstract 3018: Differential diagnosis of hematologic and solid tumors using targeted transcriptome and artificial intelligence.
Presenter: Hong Zhang | Poster: 10
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3018
------------------------------------------------------------------------------------------------------------------------
Abstract 3019: AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images.
Presenter: Gowhar Shafi | Poster: 11
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3019
------------------------------------------------------------------------------------------------------------------------
Abstract 3020: A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.
Presenter: Dmitry Zarubin | Poster: 12
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3020
------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration